Lava Therapeutics makes cuts to its headcount
22 Aug 2023
Radiation Therapy
Lava Therapeutics said Tuesday that it cut 36% of its staff after the biotech stopped all work on a therapy looking to go after CD1d-expressing hematological tumors.
The company employed 69 full-time employees as of Dec. 31, 2022. It told investors this week that its cash runway now extends into 2026, and it’s prioritizing its work on LAVA-1207, a metastatic castration-resistant prostate cancer treatment in Phase I/IIa. Lava also expects more data on the drug within the next 12 months.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.